NASDAQ:URGN Urogen Pharma (URGN) Stock Price, News & Analysis $48.12 -0.88 (-1.80%) Closing price 08/13/2026 04:00 PM EasternExtended Trading$48.07 -0.05 (-0.10%) As of 08:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Urogen Pharma Stock (NASDAQ:URGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Urogen Pharma alerts:Sign Up Key Stats Today's Range$47.67▼$49.6050-Day Range$26.85▼$49.0052-Week Range$15.86▼$49.67Volume859,975 shsAverage Volume897,834 shsMarket Capitalization$2.35 billionP/E RatioN/ADividend YieldN/APrice Target$48.78Consensus RatingModerate Buy Company Overview UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists. The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer. Jelmyto represents the first FDA-approved therapy for this indication, offering a minimally invasive, kidney-sparing alternative to surgery. Beyond Jelmyto, UroGen’s pipeline includes UGN-102, an investigational mitomycin solution under study for interstitial cystitis/bladder pain syndrome, and earlier-stage programs targeting other urologic and ophthalmic conditions leveraging the RTGel platform. UroGen markets its products primarily in the United States and is pursuing regulatory submissions in Europe and other global regions. The company’s management team is led by Co-Founder and Chief Executive Officer Tomer Kariv, supported by Chief Operating Officer Vas Narasimhan and Chief Medical Officer Philip Isaacs, among others. UroGen collaborates with key opinion leaders in urology to advance its clinical programs and expand patient access to novel in-office therapies.AI Generated. May Contain Errors. Read More Urogen Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreURGN MarketRank™: Urogen Pharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 642nd out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingUrogen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Urogen Pharma is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageUrogen Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Urogen Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Urogen Pharma are expected to grow in the coming year, from ($0.20) to $3.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Urogen Pharma is -24.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Urogen Pharma is -24.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.86% of the float of Urogen Pharma has been sold short.Short Interest Ratio / Days to CoverUrogen Pharma has a short interest ratio ("days to cover") of 6.64.Change versus previous monthShort interest in Urogen Pharma has recently decreased by 19.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUrogen Pharma does not currently pay a dividend.Dividend GrowthUrogen Pharma does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.89 News SentimentUrogen Pharma has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Urogen Pharma this week, compared to 4 articles on an average week.Search Interest8 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows4 people have added Urogen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Urogen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $892,661.00 in company stock.Percentage Held by Insiders4.80% of the stock of Urogen Pharma is held by insiders.Percentage Held by Institutions91.29% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Urogen Pharma's insider trading history. Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urogen Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. URGN Stock News HeadlinesUroGen (URGN) Q2 2026 Earnings Call TranscriptAugust 12 at 11:33 PM | finance.yahoo.comUroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In FocusAugust 9, 2026 | finance.yahoo.comBuffett's Final Warning: "The Dollar Is Going to Hell"The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defense budget. There's no way to tax our way out. No way to cut our way out. The government has exactly one move left: Pump trillions into AI to outgrow the debt. And the asset class profiting from these trillions in spending. BlackRock is buying. Goldman Sachs is buying. Gartner is calling it the next decade defining boom. The last time a similar setup formed, early investors saw gains of up to 12,480%. I've put together a workshop breaking this down in detail. I'll name the asset class and show you exactly how to profit from this $39 trillion debt crisis.August 14 at 1:00 AM | Decentralized Masters (Ad)Urogen Pharma (NASDAQ:URGN) Price Target Raised to $75.00August 9, 2026 | americanbankingnews.comUroGen Pharma Ltd URGNAugust 8, 2026 | morningstar.comMUroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call TranscriptAugust 5, 2026 | seekingalpha.comUroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and HighlightsAugust 5, 2026 | markets.businessinsider.comUroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026July 30, 2026 | markets.businessinsider.comSee More Headlines URGN Stock Analysis - Frequently Asked Questions How have URGN shares performed this year? Urogen Pharma's stock was trading at $23.42 at the beginning of the year. Since then, URGN stock has increased by 105.5% and is now trading at $48.12. How were Urogen Pharma's earnings last quarter? Urogen Pharma (NASDAQ:URGN) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by $0.02. The company had revenue of $72.46 million for the quarter, compared to analysts' expectations of $63.55 million. Read the conference call transcript. When did Urogen Pharma IPO? Urogen Pharma (URGN) raised $58 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 4,473,373 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. Who are Urogen Pharma's major shareholders? Top institutional investors of Urogen Pharma include BlackRock Inc. (6.57%), Rice Hall James & Associates LLC (0.62%), Hennion & Walsh Asset Management Inc. (0.57%) and Bank of New York Mellon Corp (0.23%). Insiders that own company stock include Mark Schoenberg, Jason Drew Smith and Chris Degnan. View institutional ownership trends. How do I buy shares of Urogen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Urogen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Urogen Pharma investors own include Voyager Therapeutics (VYGR), AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/05/2026Today8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 URGN's financial health is in the Green zone, according to TradeSmith. URGN has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:URGN CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees200Year Founded2004Price Target and Rating Average Price Target for Urogen Pharma$48.78 High Price Target$75.00 Low Price Target$33.00 Potential Upside/Downside+1.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$153.49 million Net Margins-51.73% Pretax Margin-51.98% Return on EquityN/A Return on Assets-43.79% Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.41 Sales & Book Value Annual Sales$109.79 million Price / Sales21.42 Cash FlowN/A Price / Cash FlowN/A Book Value($2.71) per share Price / Book-17.76Miscellaneous Outstanding Shares48,880,000Free Float46,535,000Market Cap$2.35 billion OptionableOptionable Beta1.57 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:URGN) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredWhy I'm sending this one to my own familyBehind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...Behind the Markets | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
